Disclaimer
Investigational drug notice
Retatrutide (developer code LY3437943) is an investigational medication currently in Phase 3 clinical trials. It has NOT been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory agency for any indication. Information on this website is based on published clinical-trial data and publicly available regulatory information and is subject to change as new data becomes available.
Research peptide warning
References to "research peptides" or "peptides" on this website are for informational purposes only. Research peptides sold online are labeled "for research purposes only" and are NOT approved for human use. This website does not sell, endorse, or recommend the purchase of research peptides for human consumption. Using non-FDA-approved substances for self-administration carries significant health risks including unknown purity, contamination, sterility issues, adulteration with other substances, inaccurate labeled concentration, and the absence of medical supervision. The U.S. Food, Drug, and Cosmetic Act prohibits the distribution and sale of unapproved new drugs for human use.
Affiliate disclosure
This website contains affiliate links to licensed telehealth providers that offer FDA-approved GLP-1 medications. We may earn a commission when readers enroll through our affiliate links. This compensation does not influence our editorial content, the factual claims made on the site, or our recommendation of physician-supervised treatment as the safest and most effective path to weight management. We disclose this relationship openly and recommend readers consider the financial incentives of any content source.
Medical disclaimer
Content on retatrutide.us.com is educational only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Do not start, stop, or modify any medication — prescribed, over-the-counter, compounded, or investigational — without consulting a qualified licensed healthcare provider who has access to your medical history, current medications, allergies, and lab results.
Individual results with any medication vary. Clinical-trial averages cited on this site may not reflect real-world outcomes for any specific individual. Side-effect rates, dosing schedules, and efficacy data reference specific trial conditions and may not generalize.
Calculator disclaimer
Dosing calculators, reconstitution calculators, and interactive tools on this site are informational tools only. They do NOT constitute medical advice, dosing recommendations, or prescription guidance. Retatrutide is not FDA-approved — no correct dose for human use has been established by any regulator. Do not use any investigational compound, whether purchased as a "research peptide" or compounded through a pharmacy, without professional medical guidance.
Clinical-trial disclaimer
Clinical-trial data cited on this site come from published peer-reviewed studies, primarily the TRIUMPH program. Phase 2 and Phase 3 results may not predict final approved efficacy or safety profiles. Trial-enrollment information links to ClinicalTrials.gov, a service of the U.S. National Institutes of Health and National Library of Medicine.
No endorsement
retatrutide.us.com is independently operated and not affiliated with Eli Lilly and Company, Novo Nordisk, any other pharmaceutical manufacturer, any telehealth provider, or any compounding pharmacy. Mentions of brands (Mounjaro, Zepbound, Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, and others) are for comparative and informational purposes only.
Errors and updates
Pharmacology, regulatory status, and pricing change. While we update regularly, we cannot guarantee that every page reflects the absolute latest information. Cross-check critical claims with primary sources (FDA.gov, ClinicalTrials.gov, NEJM) before acting on them.
Limitation of liability
retatrutide.us.com and its operators shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising out of any use of, or any inability to use, this website or any information on it. Use of this website is at your sole risk.
Last updated: 2026-04-20.